BD Announces Second Fiscal Quarter Results; Reaffirms Fiscal 2021 Guidance
- Second fiscal quarter revenues of $4.9 billion grew 15.4% on a reported basis. On a currency-neutral basis, revenues increased 12.2%.
- BD s COVID-19 testing sales were $480 million, including BD Veritor™ Plus System revenues of $290 million.
- BD s core growth led by strong growth in Medication Delivery Solutions (up 10.4%), Pharmaceutical Systems (up 15.4%), and Biosciences (up 16.3%) on a reported basis.
- Second fiscal quarter GAAP diluted earnings per share (EPS) increased 77.4% year-over-year to $0.94.
- Adjusted EPS increased 25.1% year-over-year to $3.19.
- BD is reaffirming its fiscal 2021 revenue growth and adjusted EPS guidance.
News provided by
Share this article
Becton Dickinson Lauded by Frost & Sullivan for Enhancing Patient Experience with Its BD Intevia™ Autoinjector
USA - English
Share this article
Share this article
The solution leverages a modular platform technology that allows rapid customization, optimizing time and cost for pharma companies
SANTA CLARA, Calif., Feb. 16, 2021 /PRNewswire/ Based on its recent analysis of the global autoinjector drug delivery market, Frost & Sullivan recognizes BD (Becton Dickinson) with a 2020 Global Technology Innovation Award. A part of its differentiated self-injection systems portfolio, the BD Intevia two-step, push-on-skin, handheld autoinjector facilitates high-viscosity biologics delivery for chronic disease therapies. BD Intevia s 1-mL and 2.25-mL dose configurations meet the demand for a delivery mechanism for viscous biologics. The drug-device combination improves the self-injection experience in home settings, which, in turn, improves disease management, patient adherence, and